Clover Health (NASDAQ: CLOV) details 2026 CMS Star Ratings for MA plans

Rhea-AI Filing Summary

Clover Health Investments, Corp. furnished an update on quality ratings for its Medicare Advantage plans following the Centers for Medicare & Medicaid Services release of 2026 Star Ratings. CMS awarded the Company’s PPO Medicare Advantage plans 3.5 Stars and its HMO Medicare Advantage plan 4.0 Stars. These 2026 Star Ratings will be used by CMS to determine payments for the Company’s Medicare Advantage plans for the 2027 payment year. The details were provided in a press release furnished as an exhibit to this report.

Insights

Healthcare policy and managed care analyst

Clover discloses 2026 CMS Star Ratings guiding 2027 MA payments.

Clover Health Investments, Corp. reported that CMS has assigned its PPO Medicare Advantage plans 3.5 Stars and its HMO Medicare Advantage plan 4.0 Stars for the 2026 Star Ratings year. These quality scores are central to how CMS benchmarks plan performance and influence the structure of payments in the Medicare Advantage program.

The filing states that the 2026 Star Ratings will affect the payment year 2027 for the Company’s Medicare Advantage plans, linking today’s quality metrics to future revenue mechanics. However, this disclosure does not compare these ratings with prior periods or discuss any related changes in membership, benefits, or margins, so the directional impact on the business cannot be assessed from this excerpt alone.

Investors may look to subsequent company communications and future periodic reports covering the 2027 payment year to understand how these ratings translate into realized revenue and profitability for the PPO and HMO product lines.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

FALSE0001801170CLOVER HEALTH INVESTMENTS, CORP. /DE00018011702025-10-092025-10-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 9, 2025

CLOVER HEALTH INVESTMENTS, CORP.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39252			98-1515192
(State or Other Jurisdiction			(Commission File Number)			(IRS Employer
of Incorporation)						Identification No.)

Address Not Applicable(1)			Address Not Applicable(1)
(Address of Principal Executive Offices)			(Zip Code)

Not Applicable(1)

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Trading

Title of each class

Symbol(s)

Name of each exchange on which registered

Class A Common Stock, par value $0.0001 per share

CLOV

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

(1) We are a remote-first company. Accordingly, we do not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, stockholder communications required to be sent to our principal executive offices may be directed to the email address: secretary@cloverhealth.com, or to our agent for service of process at The Corporation Trust Company, 1209 Orange Street, Wilmington, Delaware 19801.

Item 7.01. Regulation FD Disclosure.

On October 9, 2025, Clover Health Investments, Corp. (the “Company”) issued a press release commenting on the Centers for Medicare & Medicaid Services (“CMS”) release of its 2026 Star Ratings for the Company’s Medicare Advantage (“MA”) plans. CMS has awarded the Company's PPO MA plans with 3.5 Stars and the Company's HMO MA plan with 4.0 Stars. The 2026 Star ratings affect the payment year 2027.

A copy of the complete press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information set forth in this Item 7.01 (including the press release in Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) List of Exhibits

Exhibit No.			Description
99.1			Press Release of the Company, dated October 9, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Clover Health Investments, Corp.

Date:

October 9, 2025

By:

/s/ Peter Kuipers

Name:

Peter Kuipers

Title:

Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

FAQ

What did CMS award for Clover Health (CLOV) 2026 Star Ratings?

CMS awarded Clover Health’s PPO Medicare Advantage plans 3.5 Stars and its HMO Medicare Advantage plan 4.0 Stars for the 2026 Star Ratings year.

How do Clover Healths 2026 Star Ratings affect future payments?

The filing states that the 2026 Star Ratings affect the payment year 2027, meaning CMS will use these ratings when determining Clover Healths Medicare Advantage payments for 2027.

Which Clover Health products are covered by the 2026 CMS Star Ratings update?

The update covers PPO Medicare Advantage plans, which received 3.5 Stars, and a HMO Medicare Advantage plan, which received 4.0 Stars.

What is the main purpose of this Clover Health 8-K filing?

The 8-K provides a Regulation FD disclosure that Clover Health issued a press release commenting on CMSs 2026 Star Ratings for its Medicare Advantage plans and furnishes that press release as an exhibit.

Is the Clover Health press release about 2026 Star Ratings part of the financial statements?

No. The 8-K states that the information in Item 7.01, including the press release in Exhibit 99.1, is furnished and not filed for purposes of Section 18 of the Exchange Act.

Where can investors find more detail on Clover Healths CMS Star Ratings disclosure?

More detail is contained in the Companys press release furnished as Exhibit 99.1, which is incorporated by reference into the 8-K under Item 7.01.